Smith & Nephew SNATS, Inc. (NYSE:SNN) Sees Significant Increase in Short Interest

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 2,910,000 shares, a growth of 54.8% from the May 15th total of 1,880,000 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 839,100 shares, the short-interest ratio is currently 3.5 days.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HSBC lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res lowered Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Finally, UBS Group lowered Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Six analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $28.00.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN traded down $0.11 during trading on Thursday, reaching $28.53. 890,947 shares of the company traded hands, compared to its average volume of 804,309. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $31.72. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. The stock has a market cap of $12.49 billion, a P/E ratio of 13.21, a PEG ratio of 0.88 and a beta of 0.68. The firm's fifty day simple moving average is $28.22 and its 200 day simple moving average is $26.92.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors have recently modified their holdings of the business. Hexagon Capital Partners LLC grew its position in shares of Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the period. Richards Merrill & Peterson Inc. grew its position in shares of Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 1,000 shares during the period. Principal Securities Inc. grew its position in shares of Smith & Nephew SNATS by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares during the period. National Bank of Canada FI grew its position in shares of Smith & Nephew SNATS by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 446 shares during the period. Finally, Bessemer Group Inc. grew its position in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.